Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MacroGenics, Inc. - Common Stock (NQ:MGNX)

1.580 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MacroGenics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why Is Macrogenics (MGNX) Stock Down 69% Today?
Macrogenics stock is down on Friday as MGNX investors react to clinical trial deaths and missed earnings for the first quarter of 2024. 
Via InvestorPlace
Topics Death
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
The biggest pre-market stock movers are ready to go as we check out all of the hottest news happening on Friday morning! 
Via InvestorPlace
The Latest Analyst Ratings For Macrogenics
 
Via Benzinga
MacroGenics Inc. (NASDAQ: MGNX) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
Akamai Technologies Issues Weak Outlook, Joins Applied Optoelectronics, JFrog And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
MacroGenics (MGNX) Q1 2024 Earnings Call Transcript
MGNX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
MGNX Stock Earnings: Macrogenics Misses EPS, Misses Revenue for Q1 2024
MGNX stock results show that Macrogenics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Macrogenics: Q4 Earnings Insights
 
Via Benzinga
A Preview Of Macrogenics's Earnings
 
Via Benzinga
Masters In Trading - Saturday, April 27
In this recap of the most recent trading session, I review my portfolio and share one of the trades taken this week. 
Via Talk Markets
Look Out For These 6 Stocks As Analysts Predicts Major Gains, One Up To 82%
Investment analysts have revised their price targets upwards for six major stocks this week, with one company expected to see an 82% surge. The revised targets include four U.S.-listed companies, with... 
Via Benzinga
MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate
Update on MacroGenics Inc's Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo) for metastatic castration-resistant prostate cancer (mCRPC). Safety and preliminary efficacy data anticipated... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on Thursday. 
Via Benzinga
Topics Stocks
MacroGenics Inc. (NASDAQ: MGNX) is a Stock Spotlight on 3/5
Via Investor Brand Network
Analyst Expectations For Macrogenics's Future
 
Via Benzinga
Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of STAAR Surgical Company (NASDAQ: STAA) rose sharply during Thursday’s session after the company issued strong preliminary first-quarter net sales guidance. STAAR Surgical shares jumped 13.3%... 
Via Benzinga
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
From MacroGenics, Inc.
Via GlobeNewswire
MacroGenics (MGNX) Q4 2023 Earnings Call Transcript
MGNX earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
MGNX Stock Earnings: Macrogenics Misses EPS for Q4 2023
MGNX stock results show that Macrogenics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
MacroGenics to Participate in Upcoming Investor Conferences
From MacroGenics, Inc.
Via GlobeNewswire
Earnings Scheduled For March 7, 2024
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
From MacroGenics, Inc.
Via GlobeNewswire
Surgery Partners Posts Weak Sales, Joins Kosmos Energy, Moderna And Other Big Stocks Moving Lower On Monday
U.S. stocks were slightly higher, with the Nasdaq Composite gaining around 10 points on Monday. Shares of Surgery Partners, Inc. (NASDAQ: SGRY) fell sharply during Monday’s session following weak... 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.